2656 State Street
Carlsbad, CA 92008
United States
619 728 4760
https://tyra.bio
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 49
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Todd Harris Ph.D. | Co-Founder, President, CEO, Secretary, Treasurer & Director | 1,07M | S.O. | 1979 |
Mr. Alan Fuhrman | Chief Financial Officer | 763,09k | S.O. | 1957 |
Dr. Hiroomi Tada M.D., Ph.D. | Chief Medical Officer | 816,31k | S.O. | 1964 |
Mr. Daniel Bensen | Co-Founder & COO | 630,8k | S.O. | 1976 |
Dr. Robert L. Hudkins Ph.D. | Chief Technology Officer | S.O. | S.O. | 1956 |
Dr. Ronald V. Swanson Ph.D. | Chief Scientific Officer | 536,19k | S.O. | 1964 |
Mr. Ali D. Fawaz J.D. | General Counsel | 629,23k | S.O. | S.O. |
Ms. Sarah Honig | Vice President of Corporate Development & Strategy | S.O. | S.O. | S.O. |
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
L’ISS Governance QualityScore de Tyra Biosciences, Inc. en date du 1 juin 2024 est 7. Les scores principaux sont Audit : 7; Société : 5; Droits des actionnaires : 9; Compensation : 7.